Review of the literature indicates that biologics, such as TNF-α inhibitors, IL-12/IL-23 inhibitors, and anti-IL-17 inhibitors, generally have favorable effects on atherosclerosis in patients with psoriasis and PsA [15–19]. The gene discussed is IL17A; the disease is psoriasis.